Table 1. Demographics – baseline characteristics.
| Eplerenone group N = 26 | Control group N = 25 | |
| Males (%) | 19 (73) | 19 (76) |
| Age (years), mean±SD | 58.3±13.4 | 58.5±12.8 |
| Smoking current (%) | 2 (8) | 4 (16) |
| Diabetes (%) | 7 (27) | 6 (24) |
| Previous CVE ∧ (%) | 6 (23) | 4 (16) |
| Weight (kg), mean±SD | 89.1±19.9 | 90.5±15.0 |
| Anti-hypertensive medication (%) | 26 (100) | 25 (100) |
| Number of anti-hypertensive drugs, median (IQR) | 2 (2–3) | 3 (2–4) |
| ACE-inhibitor | 13 (50) | 14 (56) |
| Angiotensin Receptor Blocker | 10 (38) | 13 (52) |
| Combined ACE-inhibitor and Angiotensin Receptor Blocker | 0 (0) | 4 (16) |
| RAS-blockade – total | 23 (88) | 23 (92) |
| Calcium Channel Blocker | 11 (42) | 10 (40) |
| Beta Blocker | 8 (31) | 12 (48) |
| Furosemide | 18 (69) | 13(76) |
| Diuretic – other | 4 (15) | 5 (20) |
| CKD stage 3/4 | 18/8 | 15/10 |
| Renal diagnosis | ||
| Chronic glomerulonephritis | 5 | 5 |
| Vascular disease | 3 | 1 |
| ADPKD | 6 | 4 |
| Diabetic nephropathy | 0 | 2 |
| Other | 1 | 5 |
| Unknown | 11 | 8 |
ACE, angiotensin converting enzyme; ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CVE, cardiovascular event, i.e. acute myocardial infarction (MI) or stroke (ischaemic or haemorraghic); IQR, inter quartile range; RAS, renin-angiotensin-system.
∧
No patients had had both stroke and MI.
All P-values >0.05.